Abacus FCF Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Abacus FCF Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4,942	Closed	-$2.01M	–	164
2023 Q4	$2.01M	Buy	4,942 +2,178	+79%	+$805K	0.58%	54
2023 Q3	$961K	Buy	+2,764	New	+$967K	0.51%	70
2022 Q2	–	Sell	-3,228	Closed	-$842K	–	185
2022 Q1	$842K	Buy	+3,228	New	+$766K	0.28%	143
2021 Q3	–	Sell	-4,605	Closed	-$894K	–	151
2021 Q2	$894K	Sell	4,605 -341	-7%	-$71.3K	0.46%	110
2021 Q1	$1.06M	Sell	4,946 -31	-0.6%	-$6.81K	0.54%	79
2020 Q4	$1.17M	Sell	4,977 -465	-9%	-$107K	0.68%	80
2020 Q3	$1.47M	Buy	5,442 +1,953	+56%	+$539K	0.79%	82
2020 Q2	$1.01M	Buy	+3,489	New	+$946K	0.96%	67

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Abacus FCF Advisors's VRTX Position: Q1 2024 in Review

Abacus FCF Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q1 2024, closing a stake of 4,942 shares — an estimated $2.01M sold.

Abacus FCF Advisors first reported a position in VRTX in Q2 2020 and held it in 8 quarters. The position peaked at $2.01M in Q4 2023. 1,493 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

Abacus FCF Advisors reported no remaining Vertex Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Abacus FCF Advisors sold 4,942 Vertex Pharmaceuticals shares in Q1 2024, an estimated $2.01M.
Abacus FCF Advisors first reported a position in Vertex Pharmaceuticals in Q2 2020 and held it in 8 quarters.
Abacus FCF Advisors's Vertex Pharmaceuticals position peaked at $2.01M in Q4 2023.
1,493 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Abacus FCF Advisors's 13F filing for Q1 2024, filed 12 Apr 2024.